From hitting new therapeutic targets to developing new diagnostic methods, aptamers are bringing much-needed solutions to drug and diagnostic development. With existing technologies covering less than 30 percent of the human proteome, there is an unmet need for biomolecular recognition in the drug target space. Aptamers are single-stranded oligonucleotides that bind a wide range of proteins with high affinity and specificity, similar to antibodies. Because of their versatility, scientists are developing aptamers to perform a variety of functions, such as binding to drug targets and acting as point-of-care and wearable biosensors.
In this roundtable event brought to you by Aptamer Group, experts from academia, industry and healthcare will discuss the need for aptamers in drug and diagnostic development, highlighting the pros and cons of working with this technology and its approach to the market across therapeutic, diagnostic and bioprocessing sectors.
Thursday, June 23, 2022
11:00 AM Eastern Time (8:00 AM PT)
This webinar will also be available on-demand.
Meet the panel
Moderator Sejal Davla, PhD Assistant Science Editor The Scientist
Netz Arroyo, PhD Assistant Professor Pharmacology and Molecular Sciences Joint Faculty, Chemical and Biomolecular Engineering Member, Institute for Nanobiotechnology Johns Hopkins University School of Medicine
Jonathan Royce, MS
Chief Executive Officer Bio-Works Technologies
Daniel Wiseman, MBCHB, PhD
Oglesby Leukaemia Research Group Division of Cancer Sciences Department of Haematology The Christie NHS Foundation Trust The University of Manchester
David Bunka, PhD
Chief Technological Officer Aptamer Group
Sponsored by
Register
You must have Javascript and Cookies enabled to access this webcast.
Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
